Synthorx Inc (NASDAQ:THOR) – Equities researchers at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Synthorx in a report issued on Wednesday, March 13th. Jefferies Financial Group analyst B. Amin forecasts that the medical instruments supplier will earn ($0.33) per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $21.00 price objective on the stock. Jefferies Financial Group also issued estimates for Synthorx’s Q2 2019 earnings at ($0.39) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($1.52) EPS, FY2020 earnings at ($2.94) EPS, FY2021 earnings at ($2.99) EPS, FY2022 earnings at ($2.98) EPS and FY2023 earnings at ($3.53) EPS.
Separately, HC Wainwright assumed coverage on shares of Synthorx in a research note on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price target for the company.
Synthorx (NASDAQ:THOR) last announced its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.77).
Several institutional investors have recently bought and sold shares of THOR. RA Capital Management LLC bought a new stake in shares of Synthorx during the fourth quarter valued at approximately $169,014,000. Orbimed Advisors LLC bought a new stake in shares of Synthorx during the fourth quarter valued at approximately $92,398,000. FMR LLC bought a new stake in shares of Synthorx during the fourth quarter valued at approximately $38,559,000. Matisse Capital bought a new stake in shares of Synthorx during the fourth quarter valued at approximately $956,000. Finally, Dean Capital Investments Management LLC bought a new stake in shares of Synthorx during the fourth quarter valued at approximately $827,000. 75.85% of the stock is owned by hedge funds and other institutional investors.
Synthorx Company Profile
Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.
Featured Story: Options Trading
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.